BPH does not require treatment and is not the target of interventions; however, BPH can lead to an enlargement of the prostate (benign prostatic enlargement [BPE] ). The prostate may cause obstruction at the level of the bladder neck (benign prostatic obstruction [BPO] ). Obstruction may also be caused by other conditions referred to as bladder outlet obstruction (BOO).
Parallel to these anatomical and functional processes, LUTS increase in frequency and severity with age. LUTS may be caused by a variety of conditions, including BPE and BPO. In this Guideline, the Panel refers to "LUTS attributed to BPH" (LUTS/BPH) to indicate LUTS among men for whom an alternative cause is not apparent.
Lower Urinary Tract Symptoms (LUTS)
In assessing the burden of disease, studies reveal a progressive increase in the prevalence of moderateto-severe LUTS, rising to nearly 50% by the eighth decade of life. 1 Others estimate that 90% of men between 45 and 80 years suffer some type of LUTS. 1 Although LUTS/BPH is not often life-threatening, the impact of LUTS/BPH on QoL can be significant and should not be underestimated.
Index Patient
The Index Patient is a male 45 who is consulting a clinician for his LUTS. He does not have a history suggesting non-BPH causes of LUTS, and his LUTS may or may not be associated with BPE, BOO, or BPH.
Sexual Dysfunction and Surgical Therapy
Given the strong observed relationship between erectile dysfunction (ED) and LUTS/BPH, this group of men is at high risk for sexual dysfunction. 2 Patients should be counselled about the sexual side effects of any surgical intervention and should be made aware that surgical treatment can cause ejaculatory dysfunction and may worsen ED.
Shared Decision Making
Patients should be provided with the risk/benefit profile for all treatment options in light of their circumstances to allow them to make informed decisions regarding their treatments.
GUIDELINE STATEMENTS
Evaluation and Preoperative Testing 1. Clinicians should take a medical history and utilize the AUA-Symptom Index (AUA-SI) and urinalysis in the initial evaluation of patients presenting with bothersome LUTS possibly attributed to BPH; select patients may also require post-void residual (PVR), A complete medical history should be taken to assess symptoms, prior procedures that could explain symptoms, sexual history, medication use, and overall health. The AUA-SI can provide clinicians with information regarding symptoms. Additionally, while a urinalysis cannot diagnose BPH, it can help clinicians to rule out other causes of LUTS not associated with BPH.
While the evidence base is limited, multiple guidelines include PVR measurement as part of the basic evaluation of LUTS. A rising PVR can indicate the need for surgical intervention, or further workup may be warranted. Patients with symptoms attributed to an elevated PVR may need to proceed on to surgery or further urodynamic testing.
Preoperative uroflowmetry can inform the urologist with reasonable certitude that BPO is causal for LUTS. In patients with catheter-dependent urinary retention who may have underactive detrusor function, a pressure flow study is advised; however, clinicians should be aware that there are such patients (e.g., those with bladder diverticulum) in whom studies inaccurately indicate a lack of detrusor contractility.
Pressure flow studies are the best means to determine the presence of BOO.
3 Non-invasive tools provide useful information, but only pressure flow studies can determine bladder function or lack thereof.
Finally, prostate volume/morphology is a critical attribute for surgical selection. Preoperative assessment may be achieved by abdominal or transrectal ultrasonography, cystoscopy, or by cross-sectional imaging using magnetic resonance imaging or computed tomography. Many patients may have had prior imaging; therefore, any such imaging obtained in the 12 months preceding the planned surgical intervention may be utilized. TURP remains the single best standard against which to measure the efficacy, effectiveness, and safety of other interventions for LUTS/BPH.
Interventions discussed in this Guideline may be reasonably compared to either monopolar or bipolar TURP regarding efficacy measures given the lack of differences between monopolar and bipolar TURP in this regard. The main difference between monopolar and bipolar TURP is TUR syndrome, which is unique to TURP. As such, safety parameters other than TUR syndrome can also be reliably compared between interventions and either form of TURP.
Previous guidelines have emphasized the fact that complications increase with increasing resection time and increasing resected tissue volume following monopolar TURP. While no clear guidelines have been established, prolonged resection times should be avoided with monopolar approaches. Bipolar TURP has a reduced risk of hyponatremia and TUR syndrome, which allows for longer resection times and surgery on larger glands. TUIP has been used to treat small prostates, usually defined as 30g, for many decades. In past updates, a large number of prospective cohort trials were analyzed, and adequate results were reported in terms of AUA-SI and Q max changes. A metaanalysis comparing TUIP with TURP after a minimum follow-up of 6 months identified a lower rate of retrograde ejaculation (18.2% versus 65.4%) and need for blood transfusion (0.4% versus 8.6%) as advantages of TUIP versus TURP. TUVP is an electrosurgical modification of the standard TURP. TUVP can utilize a variety of energy delivery surfaces with saline and bipolar energy. Compared to traditional loops, the various TUVP designs hope to improve upon visualization, blood loss, resection speed, and patient morbidity.
Photoselective Vaporization of the Prostate (PVP) 13. Clinicians should consider PVP as an option using 120W or 180W platforms for patients for the treatment of LUTS/BPH. (Moderate Recommendation; Evidence Level: Grade B)
Men considering PVP should be informed of the similar outcomes with regards to symptomatic improvement in LUTS/BPH and complications versus TURP. In a multicenter randomized controlled trial comparing the 180W PVP to TURP, Figure. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia algorithm 24-month data reported similar adverse events related to urinary incontinence, need for blood transfusion, and overall need for reoperation between the two modalities.
6e8 While the I-PSS at 24 months was 5.9 for TURP (compared to 6.9 for PVP), this difference did not meet the non-inferiority criteria in the study. In comparing PUL with TURP in the BPH6 study, a lower proportion of individuals in the PUL group responded to treatment at 12 months as measured by the I-PSS reduction goal of 30% (73% versus 91%; P¼.05). At 24-months follow-up, the mean difference between PUL and TURP was 6.1 points favoring TURP. Additionally, Q max was significantly lower with PUL at all follow-up intervals.
9,10 Measures of erectile function were similar between groups at all time points, but ejaculatory function based on Male Sexual Health Questionnaire for Ejaculatory Dysfunction scores favored PUL. Similarly, McVary et al.
11 demonstrated that there was no evidence of de novo ejaculatory dysfunction or ED seen with PUL procedures, and ejaculatory bother improved by 40% at 1 year (p<0.001). Intensity of ejaculation and amount of ejaculate improved by 23% and 22%, respectively (p<0.001).
Regarding PUL compared with sham (L.I.F.T. Study), 12e15 mean change from baseline I-PSS (MD: -5.2; CI: -7.45, -2.95) favored PUL. Mean change in Q max at 3 months was higher for those who underwent the PUL (4.3mL/s) compared to sham (2.0mL/s), P¼.005. Of the participants randomized to PUL, five-year follow-up data showed slight decreases in mean I-PSS improvement and stable QoL scores; however, both remained significantly improved from baseline. Data showed non-significant differences in sexual function between PUL and sham groups. Reoperation due to symptom recurrence at 5 years was reported for 19 of 140 participants with 6 receiving additional PUL implants and 13 undergoing TURP or laser procedures. Removal of implants was required in 13 participants while 15 participants were taking LUTS medications.
Given the study limitation of PUL to prostates <80g without obstructive lobes, the Panel recommends that clinicians limit this procedure to such patients until further data are available to indicate safety in other patient populations.
Transurethral Microwave Therapy (TUMT) 16. TUMT may be offered to patients with LUTS/BPH; however, patients should be informed that surgical retreatment rates are higher compared to TURP. (Conditional Recommendation; Evidence Level: Grade C)
Evidence regarding efficacy, symptom improvement, adverse events, and urinary flow rates are inconsistent. Four trials compared TUMT to TURP or control.
16e23 Response to treatment was similar between the TUMT and TURP groups, while reoperation was significantly higher with TUMT (9.9%) compared to TURP (2.3%). Incontinence through long-term follow-up was significantly lower with TUMT (0.7%) compared to TURP (3.9%). ED was similar for TUMT (6.3%) compared to TURP (11.5%).
Water Vapor Thermal Therapy 17. Water vapor thermal therapy may be offered to patients with LUTS/BPH provided prostate volume <80g; however, patients should be informed that evidence of efficacy, including longer-term retreatment rates, remains limited. (Conditional Recommendation; Evidence Level: Grade C)
18. Water vapor thermal therapy may be offered to eligible patients who desire preservation of erectile and ejaculatory function. (Conditional Recommendation; Evidence Level: Grade C)
One double-blind trial 24e26 compared water vapor thermal therapy to sham in men with prostate volume <80g. Response to treatment through 3 months was significantly greater in the water vapor thermal therapy group (74%) compared to sham (31%). Mean changes from baseline in I-PSS and I-PSS-QoL at 3 months were greater in the treatment group compared to sham with a MDD of >3 points (MD: -6.9; CI: -9.1, -4.8). Two-year results showed sustained improvements for the I-PSS, I-PSS-QoL, and Q max , with scores remaining significantly improved from baseline. The incidence of non-serious transient adverse events was significantly higher in the water vapor thermal therapy group. No de novo ED was reported long term, and no significant changes in IIEF-EF scores or ejaculatory functions scores were observed compared to baseline.
Transurethral Needle Ablation (TUNA)

TUNA is not recommended for the treatment of LUTS/BPH. (Expert Opinion)
The lack of peer-reviewed publication in the literature review timeframe meeting the inclusion criteria and the decreasing clinical relevance resulted in a lack of enthusiasm by the Panel to recommend TUNA for the treatment of LUTS attributed to BPH.
Laser Enucleation 20. Clinicians should consider holmium laser enucleation of the prostate (HoLEP) or thulium laser enucleation of the prostate (ThuLEP), depending on their expertise with either technique, as prostate size-independent suitable options for the treatment of LUTS/ BPH. (Moderate Recommendation; Evidence Level: Grade B)
Due to the chromophore of water and minimal tissue depth penetration with both holmium and thulium, these two lasers achieve rapid vaporization and coagulation of tissue without the disadvantage of deep tissue penetration. They have better coagulative properties in tissue than either monopolar or bipolar TURP, and combined with their superficial penetration, both are reasonable for endoscopic enucleation. Given the heterogeneity in the sparsely available literature in addition to safety concerns regarding radiation exposure, post-embolization syndrome, vascular access, technical feasibility, and adverse events, it is the opinion of the Panel that PAE should only be performed in the context of a clinical trial until sufficient evidence from rigorously performed studies is available to indicate benefit over other more well established therapies. 28e40 Additionally, anticoagulation/ antiplatelet therapy has not been shown to adversely affect outcomes of HoLEP procedures, other than a slightly increased duration of bladder irrigation and hospital stay.
Medically Complicated Patients
41
Multiple studies have found that PVP is safe and effective for patients who continue their anticoagulant/antiplatelet therapy, with negligible transfusion rates. However, surgeons should be aware that longer catheterization and irrigation with an increased rate of complications has been reported, and delayed bleeding is more pronounced in these patients.
42e45
FUTURE DIRECTIONS
There are enormous gaps in knowledge and, therefore, ensuing opportunities for discovery. These include but are not limited to many unanswered questions related to the role of inflammation, metabolic dysfunction, obesity, and environmental factors in etiology, as well as the role of behavior modification, self-management, and evolving therapeutic algorithms in both the prevention and progression of disease. While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated. As medical knowledge expands and technology advances, the guidelines will change. Today these evidence-based guidelines statements represent not absolute mandates but provisional proposals for treatment under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician judgment in individual cases.
Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Conformance with any clinical guideline does not guarantee a successful outcome. The guideline text may include information or recommendations about certain drug uses ('off label') that are not approved by the Food and Drug Administration (FDA), or about medications or substances not subject to the FDA approval process. AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to carefully follow all available prescribing information about indications, contraindications, precautions and warnings. These guidelines and best practice statements are not intended to provide legal advice about use and misuse of these substances.
Although guidelines are intended to encourage best practices and potentially encompass available technologies with sufficient data as of close of the literature review, they are necessarily time-limited. Guidelines cannot include evaluation of all data on emerging technologies or management, including those that are FDA-approved, which may immediately come to represent accepted clinical practices.
For this reason, the AUA does not regard technologies or management which are too new to be addressed by this guideline as necessarily experimental or investigational.
